3 Min Read
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index e-mini futures fell slightly on Tuesday, suggesting the market's recent trend of slight moves and low volume would continue in the next-to-last trading day of the year. Dow Jones industrial average futures were down 0.20 percent at 17,946, S&P 500 futures were down 0.28 percent at 2,080 and Nasdaq 100 futures were down 0.23 percent at 4,301.
** CIVEO CORP, Monday close $8.27, -40.51 pct premarket
The company, which provides temporary housing for oilfield workers and miners, slashed its workforce on Monday and said revenue could fall by a third as slumping crude prices force oil producers to cut costs.
** NEURODERM LTD, Monday close $6.18, +31.88 pct premarket
The pharma company said data from a mid-stage study suggested that a higher dose of its Parkinson's drug could provide an alternative to treatments that require surgery.
** TEKMIRA PHARMACEUTICALS CORP, Monday close $13.86, +3.54 pct premarket
Shares of the Canadian drugmaker rose a day after a female healthcare worker in Glasgow was diagnosed with Ebola. Tekmira said last week that it would supply one of its experimental Ebola treatments for clinical studies to be conducted in West Africa next year.
The World Health Organization said on Monday that the number of people infected by Ebola in Liberia, Sierra Leone and Guinea - the worst affected by the outbreak - has passed 20,000, with more than 7,842 deaths in the epidemic so far.
** BG MEDICINES INC, Monday close $0.32, +71.88 pct premarket
The U.S. Food and Drug Administration approved the automated version of the company's BGM Galectin-3 test, which is used to measure galectin-3 protein levels in blood plasma.
** ONCOGENEX PHARMACEUTICALS INC, Monday close $2.17, +3.23 pct premarket
The company said it would regain rights to the experimental cancer drug, custirsen, from Teva Pharmaceutical Industries Ltd , triggering a $27 million payment from Teva. Custirsen, OncoGenex's lead drug candidate, has failed a late-stage prostate cancer trial and is undergoing late-stage development for use in lung cancer. OncoGenex will now assume responsibility for all custirsen-related expenses.
** ARIAD PHARMACEUTICALS INC, Monday close $6.9, +1.45 pct premarket
The drugmaker entered into a distributorship deal with privately held Angelini Pharma. The deal gives Angelini exclusive rights to market Ariad's cancer drug, Iclusig, in seven Central and Eastern European countries. (Compiled by Manya Venkatesh in Bengaluru; Editing by Kirti Pandey)